Given Imaging CEO Gavriel Meron plans to sell 100,000 shares
The shares, which Meron will obtain on the exercise of options, will be sold at a minimum price of $32.
Globes correspondent 8 May 05 17:04
Yoqne'am-based Given Imaging (Nasdaq: GIVN; TASE: GIVN) has announced today that its president and CEO Gavriel Meron has implemented a stock trading program in accordance with Rule 10b5-1 under the US Securities Exchange Act of 1934. The plan complies with the company's trading policy.
Meron beneficially owns 844,209 ordinary shares of the company, including shares owned outright and vested options, and an additional 211,084 unvested options.
Meron will sell up to 100,000 shares that he is eligible to obtain upon the exercise of stock options in order to achieve limited diversification and liquidity. 4,000 shares may be sold each week at a share price of at least $32 per share.
If at any given week shares are not trading at or above this price, and the shares covered by the plan are not sold, then the unsold shares will be carried forward and accumulated for sale in future weeks. Transactions under the plan will commence no earlier than May 20, 2005, and may continue until the earlier of the sale of all 100,000 ordinary shares covered by the plan and May 19, 2007.
Given Imaging shares closed at $24.97 on Friday, so that they will have to rise by 28% for the plan to come into effect. The last time Meron sold shares in Given Imaging was in the context of the company's secondary stock issue, which took place at the price of $32.
Rule 10b5-1 allows corporate insiders to establish prearranged written plans to buy or sell a specified number of shares of company stock over a predetermined period of time.
Published by Globes [online], Israel business news - www.globes.co.il - on May 8, 2005
Made my re-entry point today in TASE.
IMHO,this was the lowest point,and an upside from current price is to be expected.
Just my 2 cents,FWIW
start of "substantial" or 'major',
Given Imaging Announces 85 Capsule Endoscopy Studies to Be Presented at Digestive Disease Week 2005
Tuesday May 10, 4:48 pm ET
YOQNEAM, Israel, May 10 /PRNewswire-FirstCall/ -- Given Imaging (Nasdaq: GIVN - News) announced today that 85 abstracts on capsule endoscopy will be presented at this year's Digestive Disease Week� 2005 (DDW�) in Chicago May 14 - 19 at McCormick Place. Given Imaging will host booth number 1024.
"Since launching the PillCam platform four years ago we have established a large footprint in the field of G.l. diagnostics and the number of studies presented this year confirms PillCam's use as a primary diagnostic tool for an ever increasing list of indications," said Gavriel D. Meron, president and chief executive officer of Given Imaging. "The data also indicates that PillCam SB is clearly the gold standard for mucosal imaging of the entire small bowel and that our newest capsule endoscope, PillCam ESO, presents a tremendous opportunity for less invasive imaging of the esophagus."
Clinical data studies to be presented on capsule endoscopy include:
* "Evaluation of capsule Endoscopy in Celiac disease Patients with
Ongoing symptoms on a Gluten-Free Diet- A prospective Blinded European
Multicenter trial" (Presentation 547) - Tuesday, May 17th at 2:30pm -
2:45pm, McCormick Place - E450A
* "Video Capsule Endoscopy for the Diagnosis of Celiac Disease:
Preliminary Results From a Multicenter International Study"
(Presentation 548) - Tuesday, May 17th at 2:45pm - 3:00pm, McCormick
Place - E450A
* "Capsule Endoscopy in Evaluation of Patients with Celiac Disease"
(Abstract M1322) - Monday, May 16th from 8am - 5pm, McCormick Place -
Chronic Liver Disease
* "The Clinical Utility of Wireless Capsule Endoscopy in Patients with
Cirrhosis, Varices, and Anemia" (Abstract S1619) - Sunday, May 15th
from 8am - 5pm, McCormick Place - Hall E
* "Capsule Endoscopy for Acute Gastrointestinal Bleeding" (Presentation
SP674) - Tuesday, May 17th at 2:15pm, McCormick Place - E353AB
Small Bowel Tumors
* "Diagnosis and Outcome of Small Bowel Tumors Found by Capsule
Endoscopy: A Three Center Australian Experience" (Abstract M1309) --
Monday, May 16th from 8am - 5pm, McCormick Place - Hall E
* "Diagnostic Value of Video Capsule Endoscopy in Carcinoid Tumors"
(Abstract M1406) -- Monday, May 16th from 8am - 5pm, McCormick Place -
* "Intestinal Tumors: Frequently Revealed by An Obscure Digestive
Bleeding (ODB) and More Easily Diagnosed by Capsule Endoscopy (VCE)"
(Abstract M1320) -- Monday, May 16th from 8am - 5pm, McCormick Place -
Great company,superb management,proven science,good potential,
bright future,and a VERY biased shareholder(me)
Thanks.Sure hope so.We know each other from this board only,but for quite a long time ,and you know i have always
stated this was a good solid company with plenty of potential and very competant management and good caring major shareholders
(no less important),even whenever i bailed out.
Having said that,there is a clear distinction in between a dream company,not judged by fundamentals,earnings and revenue,and a mature company such as GIVN came to be.
By this stage of GIVN s lifecycle,the company is scrutinised/judged by normal factors applicable to any other "normal" company.
Pleased as i am to see GIVN at this stage,and how analysts get disappointed by a miss of a cent or two per share,it is the most "cruel"
As a (more)mature company,TACHLES - GIVN has to come up with SOMETHING major.
If not,my move will be proven NOT smart at all.
I am in,however,hoping for the best but well prepared for the worst.
Yes. To repeat myself the news is that the capsule for the colon,which is the gold mine for this company, will be starting testing.This will be announced at the GI meetings (see my last post for website). This was announced in the conference call but I do not think anyone who is not very familiar with the meaning of this picked up on how important this will be. I expect the stock will continue to rise in anticipation of the Gi meetings.
Thanks and good luck.
And most of all i hope i am proven right in my estimate.
I always claimed the company was good with lots of potential,however i do NOT believe in breaking one's head,especially when it's mine.
I am not adding a strong buy sentiment until some SOLID medical news, or other substantial developments surface.
Hopefully it will occur soon.